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Abstract
Background: Comprehensive mutational profiling data now available on all major cancers have led to proposals of
novel molecular tumor classifications that modify or replace the established organ- and tissue-based tumor typing.
The rationale behind such molecular reclassifications is that genetic alterations underlying cancer pathology predict
response to therapy and may therefore offer a more precise view on cancer than histology. The use of individual
actionable mutations to select cancers for treatment across histotypes is already being tested in the so-called
basket trials with variable success rates. Here, we present a computational approach that facilitates the systematic
analysis of the histological context dependency of mutational effects by integrating genomic and proteomic tumor
profiles across cancers.
Methods: To determine effects of oncogenic mutations on protein profiles, we used the energy distance, which
compares the Euclidean distances of protein profiles in tumors with an oncogenic mutation (inner distance) to that
in tumors without the mutation (outer distance) and performed Monte Carlo simulations for the significance
analysis. Finally, the proteins were ranked by their contribution to profile differences to identify proteins
characteristic of oncogenic mutation effects across cancers.
Results: We apply our approach to four current proposals of molecular tumor classifications and major
therapeutically relevant actionable genes. All 12 actionable genes evaluated show effects on the protein level in the
corresponding tumor type and showed additional mutation-related protein profiles in 21 tumor types. Moreover,
our analysis identifies consistent cross-cancer effects for 4 genes (FGFR1, ERRB2, IDH1, KRAS/NRAS) in 14 tumor
types. We further use cell line drug response data to validate our findings.
Conclusions: This computational approach can be used to identify mutational signatures that have protein-level
effects and can therefore contribute to preclinical in silico tests of the efficacy of molecular classifications as well as
the druggability of individual mutations. It thus supports the identification of novel targeted therapies effective
across cancers and guides efficient basket trial designs.
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Background
Next-generation sequencing has facilitated comprehen-
sive mutational profiling of all major cancers and has led
to the discovery of oncogenic driver mutations, many of
which can be targeted therapeutically [1–3]. Following
the conventional organ- and tissue-based WHO classifica-
tion of tumors and standard clinical trial design, precision
therapies targeting these driver mutations are usually eval-
uated for a specific cancer type. However, sequencing data
has shown that actionable mutations, albeit with different
frequencies, occur across cancers, which has raised the
question about histotype-independent therapies and novel
ways of tumor classifications no longer relying on hist-
ology but on genetic profiles. Recent studies propose such
molecular tumor classifications, which extend or even re-
place the histology-based tumor typing as implemented by
the World Health Organization (WHO) [4, 5]. Although
different, these approaches share the common idea that
molecular (mutational) profiles govern tumor pathology
and should therefore replace histotyping in diagnostics
and therapy selection [6]. That targeted therapies against
the same single molecular alteration can be effective
across cancers, as shown, for instance, by the efficacy of
anti-Her2 therapy in both gastric and breast cancers [7, 8]
or the clinical benefit from inhibition of mutated cKIT in
gastrointestinal stromal tumors (GIST) and melanoma or
mastocytosis [9, 10]. However, the fact that inhibition of
BRAF mutated at V600 is effective in melanoma but
not in colorectal cancer [1, 11, 12] is a prominent ex-
ample against the general transferability of knowledge
on a single actionable mutation from one histological
tumor type to another. This observation is corroborated
by recent basket trials that point to histology as an import-
ant predictor of response to targeted therapy against ac-
tionable mutations [13, 14].
The reasons for the variable therapeutic utility of
genetic aberrations across cancers is likely due to the
complex molecular “background” observed in many tu-
mors. Using mutational profiles or just single genetic
aberrations, as is the case in the current basket trials, is
unlikely to cover the full scope of (tissue-specific) mo-
lecular effects including epigenetic mechanisms and
downstream regulation such as post-translational modi-
fications. However, it would be highly desirable for
therapy selection in individual patients and clinical trial
design to predict genes with similar functional effects
across histotypes.
To this end, we developed a computational approach
that integrates genomic and proteomic data from 3590
tumors to analyze the impact of genetic aberrations on
protein profiles and gauge the functional effects of muta-
tional profiles across 32 different cancers. We apply our
approach to evaluate the (functional) relevance of the
abovementioned molecular tumor classifications and
systematically analyze the effects of all major driver
mutations on protein profiles across all major cancers.
Figure 1 provides an overview of our approach and
compares it to traditional tumor classifications.
Methods
Genetic data
Two TCGA data types were used: protein expression
and somatic mutations. Data of all diseases available
without limitation was used. For somatic mutation data,
we used data processed with Oncotator [15]. TCGA data
was downloaded from Broad Institute [16] via GDAC
firehose http download. For pan-organ protein expres-
sion analysis, we used TCPA data [17] (https://
www.tcpaportal.org/tcpa/; TCGA-PANCAN16-RBN.csv).
Batch removal
To remove possible TCGA batch effects on protein ex-
pressions influencing our analysis, we excluded 21
batches with a total of 393 TCGA cases (details given in
Additional file 1: Table S1). To identify problematic
batches, we used the R package of mbatch (http://
bioinformatics.mdanderson.org/tcgambatch/). For each
histological tumor type, we sequentially removed batches
until the value of the Dispersion Separability Criterion
(DSC) was below 0.3 and the corresponding p value was
below 0.05. The batch to remove next was chosen by
iteratively removing one of the current batches, calcu-
lating the DSC value for a remaining set of batches,
and adding the batch again. The batch with the low-
est DSC for the remaining batches after its removal
was chosen.
Tumor classifications
Tumor classifications proposed by Ciriello et al. [4] and
Hoadley et al. [5] were investigated. We also tested a clas-
sification we published earlier based on the definition of a
nearest mutational neighbor by Heim et al. [18]. The fourth
classification we analyzed is based on the genes TP53,
TTN, and BRAF. These three genes were chosen after a
principal component analysis of mutational profiles showed
they identify the coarse cluster structure of the data when
mutational profiles are represented as two-dimensional
vectors (more details given in Additional file 1, section
“Genetic complexity reduction”). Additionally, classes com-
prising of cases with typical alterations in actionable genes
such as BRAF V600 were evaluated. The classifications
based on actionable genes are binary; this means for each
actionable gene, the classification has two classes—one
class is comprised of cases having that actionable mutation
the other of those without. All analyses described in this
paper were performed for each classification separately.
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Discriminability analysis
To test whether there are differences in protein expression
between cases of different classes from the same tumor,
we computed the energy distance of the two groups com-
posed by those cases. Energy distance measures the
homogeneity of protein expression of group A (for ex-
ample, skin cancer melanoma BRAF V600E-positive
cases) and group B (skin cancer melanoma BRAF
V600E-negative cases) separately and compares it to the
homogeneity of cases from A to B taken together. A
smaller (negative) energy distance indicates the protein
expressions of the cases from the two groups are discrim-
inable. Let c1;A1 to c
1;A
i be the group g
1, A of i cases with
histological tumor type A assigned to class 1, c2; A1 to c
2;A
j
be the group g2, A of j cases with histological tumor type A
assigned to class 2, and let d(cx, cy) be the
Euclidean distance of two cases in protein space, than the
energy distance de1A, 2A of the two groups g
1, A and g2,




























To test whether the distance between two groups is sig-
nificant or within random range, we ran Monte Carlo sim-
ulations (1 million runs) to determine the p value
corresponding to the measured distance. In each run, we
Fig. 1 Graphical abstract/flow diagram of study. Top: In the WHO classification, tumors are typed by their histomorphological properties which
are refined by additional molecular markers based on which targeted therapies are selected if actionable mutations are found. Middle: Novel
molecular tumor classifications propose to ignore histological properties and fully rely on comprehensive molecular profiling dominated by
genomic techniques based on which targeted therapies are selected, which are, however, not always effective if histotypes are ignored. Bottom:
The approach we propose complements genomic profiling by the integration of proteomic data to estimate the functional relevance of
mutations and predict the efficacy of targeted therapies. Our results show that actionable mutations are associated with distinct proteomic
profiles and are indicative of drug response in cell line data
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calculated the energy distance of two groups, which were
randomly created from the same cases as originally used
and having the same sizes i and j as the original groups.
The frequency of the two random groups having a lower
or equal energy distance (stronger or equal differences in
protein expressions) than the groups based on the original
genetic classes yields the p value. Benjamini-Hochberg
procedure (p values given in the text are unadjusted) and
p value thresholding (p < 0.05) were used to find the pairs
of genetic classes with significantly different protein ex-
pressions for each histological tumor type. This results in
a list of pairs of groups (a pair of groups are two groups of
cases from the same histotype with different genetic clas-
ses) with significant differences in protein expressions be-
tween the two groups. As a trade-off between the
reliability of results and investigating as many classes as
possible, we compared only groups with five or more
cases.
Determine characteristic proteins
For each pair of groups with significant differences in pro-
tein expression, we also calculated the contribution of
each protein to the total energy distance of the two
groups. Therefore, the energy distance of the two groups
is calculated as described above, with the modification
that the distance of two cases is not given by their Euclid-
ean distance in protein space but by the difference in ex-
pressions for a specific protein only. Calculated for each
protein separately, the contribution of each protein to the
distance is known. As a result, we were able to filter for
those proteins that have the strongest effect on the dis-
criminability of the two different groups. The proteins
with the strongest contribution to the difference of the
two groups are those with the most negative contribution
values. Proteins with a negative contribution value are
considered to be characteristic proteins if the absolute
value of the contribution of the protein is higher than the
highest positive contribution value among all proteins.
We chose this dynamic threshold as it can be considered
as an estimate for the maximum noise of the contribution
signals. Characteristic proteins are then divided into two
sets by calculating their mean values among the cases of
the two groups. The proteins with higher mean values in
group A are considered to have significantly increased ex-
pression values in group A cases compared to group B
cases and vice versa. We chose this test for characteristic
proteins over, for example, the U test because it puts em-
phasis on the proteins with larger differences rather than
proteins with smaller yet significant differences between
the two groups of cases.
Definition of cross-cancer effects
To address the question of how mutational differences
between two classes affect protein expressions in more
than one histotype in the same way, we performed a
cross-cancer effect analysis. We therefore searched the
list of discriminable group pairs for group pairs with the
same classes but different histological tumor types. The
result would be two group pairs pA = (g1, A, g2, A) and
pB = (g1, B, g2, B). Associated with each pair of groups are
two sets of characteristic proteins. Set sA1 is the set of
characteristic proteins for pA that are increased for class
1, set sA2 is the set of characteristic proteins for pA that
are increased for class 2, set sB1 is the set of characteristic
proteins for pB that are increased for class 1, and set sB2
is the set of characteristic proteins for pB that are in-
creased for class 2. We then compute the number of inter-
secting characteristic proteins by ni ¼ jsA1 ∩sB1 j þ jsA2 ∩sB2 j
and use one-tailed Fisher’s exact test to determine whether
the number of intersecting characteristic proteins is sig-
nificant relatively to the number of characteristic proteins
of both groups and the total number of proteins used
(120). The p value for all group and histological tumor
type pairs were also false positive corrected with the
Benjamini-Hochberg procedure.
Results
Proteomic profiles are more histotype-specific than
genomic profiles
The attempts to propose novel molecular tumor classifi-
cations are mainly based on the observation that gen-
omic profiles show substantial similarities across
histological tumor types and are often inconsistent with
histology [4, 18]. Because this study aims at evaluating
the functional relevance of these molecular classifications
based on proteomic profiles, we first studied whether the
observed inconsistencies between genomic and histo-
logical typing also exist on the level of proteins by
re-applying the analysis presented by Heim et al. [18] to
corresponding reverse-phase protein array data available
through The Cancer Protein Atlas (TCPA) [17].
Our analysis showed that mutational and histological
tumor types agreed for only 45% of the 3590 cases, for
which both protein and mutational data were available
(47% if combining colon and rectal cancer as a single
histotype). For protein profiles, the analysis demon-
strates a consistency with histotypes in 94% of the cases
(95.6% if colon and rectal cancer combined, Fig. 2). The
only relevant cross-cancer similarities on the protein
level exist for colon and rectal cancer (1.6% of all cases)
and, moreover, lung squamous and adenocarcinoma
(1%), which arise in the same organ.
To further examine the proteogenomic relations and
to test if distinct mutations converge on similar pro-
tein profiles, we performed a gene set enrichment ana-
lysis that evaluated if the used gene set contains a
significant number of genes corresponding to
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differentially expressed proteins. We found such rela-
tions in 24 out of 76 pair-wise molecular class compar-
isons, all of which were histotype-dependent (for
details about the method, see Additional file 1, section
“The relation between mutational and protein pro-
files,” and for results, see Additional file 2: Table S2).
Moreover, we tested if the fact that TCGA/TCPA of-
fers only a limited panel of less than 200 proteins may
introduce a bias when comparing cross-cancer similarities
between genomic and proteomic data. Also, evaluating
functional groups of genes may show different patterns of
genetic profiles. To address these issues, we first re-per-
formed our similarity analysis for only the genes with cor-
responding proteins in the TCPA/RPPA data. Second, we
assigned genes to the c6 gene set (oncogenic signaling)
from MSigDB (Broad Institute). These controls showed
that apart from minor quantitative differences, the overall
pattern of substantial cross-cancer similarities is consistent
between both approaches and our original findings shown
in Fig. 2 (for details, see Additional file 1, section “Cross-
cancer similarities for different gene sets”).
In summary, while substantial genetic cross-cancer
similarities exist, our analysis points to a pronounced
organ-type specificity of the observed protein profiles.
At this point, it is unclear whether the reason for this in-
consistency between genetic and protein profiles is the
differential translation of genetic profiles into protein levels
in different cancer types, or organ- and tissue-specific pro-
tein base levels that are modulated by mutations—or a
combination of both.
Histotype specificity of genetic classifications and pan-
cancer effects
Based on the findings that global genetic cross-cancer
similarities are not reflected in corresponding protein
pattern similarities, we evaluated to what extent tumor
classifications based on molecular alterations are impact-
ing protein profiles. We systematically compared if, and
which, genetic classes affect proteins (i.e., which classes
are discriminable on the level of protein profiles) for 3
molecular cancer classification approaches [4, 5, 18] and
a computational approach based on reducing genetic
complexity for 30 different histological tumor types.
Subsequent to the identification of molecular classes
with impact on the protein level as an indicator of func-
tional relevance within each histotype, we also compared
the molecular class discriminability on the protein level
across histological tumor types to determine which of
the molecular classes found to be functionally relevant
in one histotype, are relevant also in another. To this
end, the following aspects are addressed for each
classification.
Fig. 2 Mutational and proteomic cross-cancer similarities. Chord diagrams show the cross-cancer similarities for somatic mutations (left) and
protein profiles (right) by computing for each case the closest molecular neighbor among all 3590 tumors for which mutational and proteomic
data were available. Chords connecting two histological tumor types indicate the number of tumors of a certain cancer that are—on the level of
mutations or protein profiles—more similar to tumors of the other type than to their own, indicating a disagreement of molecular and histological
type. Hill-like structures, on the other hand, indicate the amount of cases where molecular and histological classes are identical. It is obvious that a
substantial disagreement exists only for mutational profiles (similar results for copy number variation, Additional file 1: Figure S4) showing agreement
between mutational and histological tumor types in only 45% of the cases, whereas protein profiles are consistent with histological tumor types in
over 94%
Heim et al. Genome Medicine           (2018) 10:83 Page 5 of 17
First, we provide a descriptive comparison between
genetic and histological classifications by evaluating the
distribution of genetic classes across the different histo-
logical classes.
Secondly, we introduce the classification effectivity
score (CES) which indicates to what extent different mu-
tational classes can be discriminated by their protein
profiles assuming that classifications are more effective
and thus clinically relevant if their (genetic) classes are
visible also on the protein level. The CES integrates the
results of the different subtests (a subtest is the pair-wise
comparison of two genetic classes with respect to their
protein profiles) into one score to describe the accuracy
of the classification with which individual classes can be
discriminated by protein profiles (i.e., the percentage of
evaluated class vs. class subtests where the protein pro-
files were found to be significantly different from each
other). The CES can be also evaluated class-wise (only
subtests using a specific class are evaluated) to describe
to what extent protein profiles of the specific class differ
from those of all other classes. In analogy to this, the
histotype-wise CES evaluates all subtests for a specific
histotype.
Thirdly, in addition to the global CES, we define the
discriminability score sdis for pairwise class comparisons.
The discriminability score measures to what extent pro-
tein profiles of histological tumor type X differ between
class A and class B (as sdis the describes the difference in
protein levels of two classes, the score is more negative
the more distinct the profiles of the two sets are). For
those subtests, we also identify those proteins for which
the profiles deviate most between two classes.
Finally, we analyze the cross-cancer protein profile ef-
fects for each classification. A cross-cancer effect is re-
ported when two genetic classes can be distinguished
from each other in protein profiles in at least two histo-
logical tumor types and if protein effect directionality is
similar across histotypes.
Overall, the four tested molecular classifications de-
fine classes that are associated with distinct protein pro-
files in some tumor types. However, protein profiles are
affected similarly across tumor types for only two class
Fig. 3 Relations of molecular classes and histological tumor types in each classification. The diagrams show the number of cases from each
histotype (top) assigned to the molecular classes (bottom). The molecular classification by Hoadley et al. is largely consistent with histotyping as a
molecular class contains cases from only 1.5 histotypes on average. Ciriello et al. shows 2.5 histotypes per molecular class, whereas the classifications
based on Heim et al. and genetic complexity reduction are substantially more distinct from histotyping as a molecular class is comprised of cases of
5.4 respectively 10.75 different histological tumor types
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pairs, and for most classes, protein profile discriminability
is dependent on tumor type.
In the proposal by Ciriello et al. [4], tumors are classi-
fied by the presence of somatic mutations and copy
number alterations in cancer-related pathways. Molecu-
lar classes are composed of, on average, 2.5 different
histotypes (range 2 to 6), and histotypes are assigned to
7.2 different molecular classes on average (range 2 to
15). For details about histotype and molecular class con-
gruence, also see Fig. 3.
The global classification effectivity score (CES) is 17%.
The highest effectivity score for a specific histotype is
Fig. 4 Reproducibility of molecular tumor classes on the level of protein profiles. The heatmaps show for each molecular tumor classification and
all histotypes the degree with which a molecular class is distinguishable from other classes based on protein profiles. Blank matrix entries indicate
fewer than five cases which were excluded from the analysis. In the classification by Ciriello et al., gynecological cancers (breast, uterine and
ovarian) show highest protein-level effects of genetic classes, whereas the molecular classes based on Heim et al. have less impact on proteins
overall. The genetic complexity reduction classification has relatively distinct protein profiles for histological tumor types. Hoadley et al. propose
classes well discriminable by protein profile (however, due to the high agreement with histotypes, only a few classes contain sufficient cases to
evaluate protein level effects)
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found for breast cancer with 36.6%. The molecular clas-
ses, which show the highest classification effectivity in
breast cancer, are C11 (66%) and C7 (60%). Yet, both
classes are separable from other classes in hardly any
other histological type (C11: CES = 11%, C7: CES = 9%
over all other histotypes). For histological tumor types
other than breast cancer, the mean classification effectiv-
ity score is 10%. Highest histotype-specific classification
effectivity scores apart from breast cancer are found for
colorectal adenocarcinoma (CES = 13%), ovarian cancer
(CES = 9%), and endometrial carcinoma (CES = 20%),
with CES = 36% for breast cancer being the highest
score, followed by endometrial carcinoma with 20% and
10% for other histotypes. Our results indicate that the
Ciriello classification is to some extent focused on breast
cancer. An overview on class and histotype classification
effectivity scores is also given in Fig. 4.
The highest molecular class discriminability score is that
within breast cancer cases for classes C11 and M1 with a
score of sdis = − 6.38 (p = 2.1e−3, based on a Monte Carlo
simulation with 1e6 random class assignment runs result-
ing in an average discriminability score srand = − 3.5e−4).
Comparing the protein expression of the two classes
shows that the average expression of Cyclin_B1 is signifi-
cantly increased for class C11 cases whereas PR, GATA3,
ER-alpha, Bcl-2, and Caveolin-1 expression values are sig-
nificantly higher for M1 cases. Interestingly, high Cyclin-
B1 and low PR expression indicate a (more aggressive)
basal subtype of breast cancer in the PAM50 profile which
indicates that the proteomic profiles at least partially cor-
relate with gene expression-based subtyping although this
cannot be comprehensively tested here due to the small
panel of available proteins.
The least pronounced but still significant class dis-
criminability is achieved for classes C12 and C5 in breast
cancer (sdis = − 0.31, p = 4.4e−3; srand = − 8.0e−5). Class C12
has significantly increased mean expression/phosphoryl-
ation for Syk, p70S6K, HER2_pY1248, EGFR_pY1068, and
HER2; class C5 is enriched for higher expression of PR,
ER-alpha, GATA3, and Cyclin_D1.
To search for consistent effects of genetic alterations
on protein profiles not just within a histological tumor
type but across tumor types, we evaluate the overlap of
proteins with altered expressions/phosphorylation for
all molecular classes that are discriminable in more
than one histotype. Pairs of molecular classes that are
discriminable in more than one histological tumor type
and therefore candidates for such an effect are, in
principle, classes C11 and M4 in breast cancer and
endometrial carcinoma, classes C11 and M5 in breast
cancer and endometrial carcinoma, and classes C3 and
M5 in breast cancer and endometrial carcinoma. How-
ever, no significant intersection of characteristic pro-
teins between breast cancer and endometrial carcinoma
can be found for any pair of classes, and therefore, no
cross-cancer effects are present for the Ciriello classifi-
cation (complete results are available in the
Additional file 3).
The classification proposed by Hoadley et al. [5] consists
of 13 different classes based on comprehensive proteoge-
nomic information. A molecular class comprises, on aver-
age, 1.5 different histological types (min 1; max 3). Classes
3, 4, 5, 6, 8, 9, and 10 comprise only of cases of a single
histotype. Cases from one histotype are assigned to 1.3
different classes on average (range 1 to 3). Compared to
Ciriello et al., the Hoadley proposal has a substantial over-
lap with the histological tumor types. In particular, five or
more cases were assigned to more than one molecular
class only for lung squamous cell carcinoma, breast can-
cer, and urothelial bladder carcinoma. Because subtests
are conducted for pairs of molecular classes within the
same histotype, only five subtests can be performed. Four
of those five class pairs show significant differences in pro-
tein expression resulting in an overall classification effect-
ivity score (CES) of 80% (urothelial bladder carcinoma
66%, breast cancer 100%, and lung squamous cell cancer
100%). The discriminability score is sdis = − 4.24 (p = 0.0;
srand = 8.1e−5) in breast cancer for molecular classes 3
and 4. The proteins with significant expression differ-
ences responsible for discriminability of classes 3 and 4
are INPP4B, ER-alpha, GATA3, PR, AR, Bcl-2, and
Cyclin_B1. Significant differences in protein expres-
sion (sdis = − 0.58; p = 1.6e−5; srand = 3.5e−5) are also
found for lung squamous cell carcinoma cases
assigned to molecular classes 1 and 2. For urothelial
bladder carcinoma, classes 1 and 8 (sdis = − 1.34; p = 7.0e−5;
srand = 2.6e−5) are discriminable as well as classes 2 and 8
(sdis = − 1.41; p = 0.0; srand = 3.2e−5). Because no pairs of
molecular classes are discriminable in more than one histo-
logical tumor type, no cross-cancer effects can be found.
Heim et al. [15] compute mutational profile similarity
classes across all tumors based on somatic mutations.
For example, a breast cancer case with a mutational pro-
file that is most similar to an ovarian carcinoma case is
assigned the class toOv. On average, cases from one his-
totype are assigned to 5.4 different classes (min 1, max
16), and one class consists of cases from 5.1 different
histological tumor types. As reported in [18] for each
“to-histotype” class, the majority of assigned cases be-
longs to this tumor type (toBRCA consists of 50% breast
cancer cases for instance).
With CES = 2%, the overall classification effectivity
score of this classification is the lowest among all tested
classifications indicating that global comparisons based
on somatic mutations only are not effective in classifying
tumors in a meaningful way if the available protein
profiles are considered relevant. Histotype-specific
classification effectivity scores are highest for breast
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cancer (2.5%), low-grade glioma (10%), gastric cancer
(7%), and thyroid carcinoma (30%). Of all classes in
this classification, toTHCA (the class consisting of
cases that have a mutation profile most similar to thy-
roid carcinoma) had the highest classification effectiv-
ity score of 8%.
For this classification, class discriminability sdis is high-
est between class toLGG (cases that are most similar to
low-grade glioma cases by their mutation profile) and
class toPRAD for low-grade glioma (LGG) (sdis = − 3.26;
p = 0.0; srand = − 6.1e−5; characteristic protein profiles in-
creased in toLGG: p70S6K_pT389; increased in ToPRAD:
YAP_pS127, HER2_pY1248, HER2, EGFR_pY1068,
EGFR_pY1173, Src_pY416, and Cyclin_D1). Also, breast
cancer cases which are similar to gastric cancer can be dis-
criminated from cases that are similar to thyroid carcin-
oma with a discrimination score of sdis = − 2.01 (p = 9.1e−5;
srand = 3.0e−4). For breast cancer cases, similar to gastric
cancer, characteristic proteins are ASNS and Cyclin_B1,
whereas for cases similar to thyroid carcinoma, charac-
teristic proteins with increased expression are Caveolin-1,
Collagen_VI, PR, MAPK_pT202_Y204, and ER-alpha.
Classes toSTAD and toTHCA can also be separated for
gastric cancer with proteins characteristic to class toS-
tad being Cyclin_B1, Caspase-7_cleavedD198, and
Claudin-7 whereas toTHCA cases have significantly in-
creased expression/phosphorylation of NF-kB-p65_p
S536 and Caveolin-1.
A cross-cancer effect is present for the histotypes
breast cancer and gastric cancer as classes toSTAD
and toTHCA show overlapping characteristic proteins
Cyclin_B1 and Caveolin-1 (p = 0.02) for those two his-
totypes. No other cross-cancer effects can be found.
In addition to the three previously published methods,
we evaluated a classification which is based on a nonlin-
ear principal component analysis of mutational profiles
which yielded the genes TP53, TTN, and BRAF as indi-
cators of high-level molecular types (Table 1). While it is
obvious that these genes are not sufficient to establish a
comprehensive molecular classification (particularly with
respect to the controversial gene TTN [19–21]), they
may be regarded as a very basic molecular typing system.
This classification scheme assigns most cases to class 0
(48% of all cases). Classes 2, 4, and 6 (no BRAF muta-
tion) are also very well populated from cases of different
histological tumor types (13%, 20%, 11%). Overall, a
molecular class on average includes cases from 10.75
histotypes (min 0; max 26). Cases of one histotype are
assigned to 2.9 different classes on average (min 1;
max 6).
The evaluation of protein profiles of the same histo-
type assigned to different classes yields an overall classi-
fication effectivity score of 16.8% which is almost as high
as the score of the Ciriello classification despite its sub-
stantially lower complexity. The highest CES is found
for adrenocortical carcinoma with 100%, although in this
case only discriminable classes 0 and 4 have sufficient
cases to be analyzed. Classes 0, 2, 4, and 6 are comprised
of breast cancer cases, and their protein profiles are
evaluated pairwise resulting in six comparisons. Of those
six comparisons, only protein profiles of class 4 and 6 do
not differ significantly. Therefore, the second highest
classification effectivity score is found for breast cancer
with 83.3% (five of six class to class comparisons). The
class with the highest classification effectivity score is
class 0 (no mutation in TP53, TTB, or BRAF) with
25.4%.
The highest class discriminability score for this classifi-
cation is found in discriminating thyroid carcinoma pro-
tein profiles for classes 0 and 1 (sdis = − 2.07; p = 0.0;
srand = − 1.3e−4; characteristic protein profiles: ER-alpha,
PR, GATA3, Bcl-2, and INPP4B increased for class 0—
increased for class 4: Cyclin_B1 and ASNS). For breast
cancer, differences in protein profiles are found between
classes 0 and 6 (sdis = − 1.85; p = 0.0; srand = 1.8e−5; char-
acteristic protein profiles increased in class 0: ER-alpha,
PR, GATA3, Bcl-2, Caveolin-1, AR, and INPP4B—for
class 6: ASNS, Caspase-7_cleavedD198, and Cyclin_B1)
and between class 0 and class 4 (sdis = − 1.64; p = 0.0;
srand = − 7.6e−5; characteristic proteins increased in class
0: ER-alpha, PR, GATA3, Bcl-2, and INPP4B—increased
in class 4: Cyclin_B1 and ASNS).
For this classification, a consistent cross-cancer effect
is found for classes 2 and 4 in both breast cancer and
endometrial carcinoma. Protein profiles of classes 2 and
4 in breast cancer differ significantly for proteins
ER-alpha, GATA3, AR, and ER-alpha_pS118 (increased
in class 2), and Cyclin_B1 and p53 (increased in class 4).
For endometrial carcinoma, protein profiles between class
2 and class 4 differ for ER-alpha, Akt_pS473, Akt_pT308,
E-Cadherin, ER-alpha_pS118, Claudin-7, and CD49b (in-
creased in class 2), and p53, Cyclin_B1, Cyclin_E1, and
Table 1 Genetic complexity reduction-based classification scheme.
The table is a complete illustration of the rules governing which
class a case is assigned by the genetic complexity reduction-based
classification
TP53 mutated TTN mutated BRAF mutated Class
No No No 0
No No Yes 1
No Yes No 2
No Yes Yes 3
Yes No No 4
Yes No Yes 5
Yes Yes No 6
Yes Yes Yes 7
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IGFBP2 (increased in class 4). With an overlap of four char-
acteristic proteins (ER-alpha, ER-alpha_pS118, Cyclin_B1,
and p53) this constitutes a significant (p = 0.0054) cross-
cancer effect.
Actionable genes are related to distinct protein profiles
across cancers
While there are attempts to re-classify cancer based on
comprehensive molecular profiles as outlined above, these
are still largely theoretical considerations. Many so-called
basket trials have already begun to evaluate the utility of
single actionable mutations for targeted treatment selec-
tion independent of the histological tumor type. However,
while some studies show that targeted therapies work in
different histological tumor types (Anti-Her2 treatment in
breast and gastric cancer, NTRK in various cancers [22]),
several recent basket trials have demonstrated that the ef-
ficacy of targeted treatments often depends on the histo-
logical tumor type [13, 14]. Using the same approach as
above, we are systematically evaluating all major action-
able somatic mutations and copy number alterations
against which drugs are approved for clinical use or which
are currently tested in clinical trials with respect to
their effects on proteins across cancers. Because we
evaluate all actionable genes across all histotypes with
sufficient numbers of mutated and wildtype cases, we
both validate our approach by showing that estab-
lished actionable genes show protein profile effects and
identify novel gene-cancer combinations for which
druggability is not yet established but for which we ob-
serve specific protein patterns. This integration of gen-
omic and proteomic data allows us to predict genetic
aberrations that are promising candidates for successful
basket trials particularly if protein profile effects show a
consistent directionality across cancers.
In our analysis, we study genes currently listed as ac-
tionable in the database OncoKB (http://oncokb.org/
#/actionableGenes) that contains information on 476
genes in 65 histological tumor types and 97 related
drugs [23] and that are sufficiently represented in The
Cancer Genome Atlas (TCGA/TCPA). OncoKB lists 12
genes with level 1 evidence (FDA-approved), 11 genes
with level 2 evidence (standard care), 26 genes in level 3
(clinical evidence), and 20 genes with biological evidence
(level 4). We used all actionable genes from evidence levels
1 to 3 with simple somatic mutations (SNPs, insertions, de-
letions) and copy number variations with a sufficient num-
ber of mutated cases (12 actionable genes). A detailed list
of evaluated actionable mutations can be found in Add-
itional file 4: Table S3. We also analyzed actionable fusions
using fusion data from [24], but due to the overall small
number of fusions, there were only four tumor type fusion
combinations that were analyzed. Results are given in Add-
itional file 1, section “Actionable Fusions.”
Overall, our analysis showed for all analyzed 12 action-
able genes (OncoKB evidence levels 1–3) that the muta-
tional status is associated with significant differences in
protein profiles in histotypes for which the respective
targeted drugs are approved or currently being clinically
tested and showed additional mutation-associated pro-
tein profiles in 9 histological tumor types. Moreover, our
analysis identifies consistent cross-cancer effects for 4
genes (FGFR1, ERRB2, IDH1, KRAS/NRAS) in 11 histo-
logical tumor types. Only KRAS/NRAS mutations in
Table 2 Comparison between the results of cell line sensitivity
of cell lines with actionable mutations and TCGA protein profile
discriminability. For each actionable gene-histotype combination,
Y = yes and N = no indicate whether cell lines with actionable
mutations show different drug response than cell lines without
actionable mutation and if protein profiles of actionable TCGA
cases of the specific histotypes have been discriminable from
non-actionable ones
Actionable gene Histotype Drug response Differences in TCGA
protein profiles
BRAF SKCM* Y Y




EGFR LUAD* Y Y

















PIK3CA BLCA Y N
HNSC N N
STAD N Y
*Histotypes where the gene is clinically established as actionable are marked.
Fisher’s exact test shows there is a significant relation between protein
discriminability and drug response (p = 0.0484)
bold: Response to targeted drugs and protein profile differences were
consistently both present (Y) or both absent (N)
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colorectal cancer do not result in discriminable protein
profiles comparing wild-type and mutated cases, whereas
an effect can be observed for thyroid cancer and melan-
oma. To provide further evidence for the significance
of this observation, we tested if protein profile dis-
criminability is more often seen in tumor types
where the gene is actionable than in non-actionable
tumor types. This showed that the actionability of
mutations is highly significantly associated with dis-
criminable protein profiles (Fisher’s exact test p <
0.0001).
To evaluate if the protein profile analysis approach
may contribute to predicting druggability of oncogenic
mutations across cancers, we validated our predictions
made for tumors from TCGA with drug response data
available for cell lines. Our results demonstrate that in
addition to confirming known druggable genes in the
available cell line data, protein profile discriminability
in between presence or absence of oncogenic mutations
is predictive of drug response in cell line data across
cancers (p = 0.048, Table 2). For more details, please
see Additional file 1 section “Cell line analysis” and
Additional file 5: Tables S4 and S5.
BRAF mutations are actionable in melanomas
(OncoKB level 1). Mutations of BRAF are frequent
enough in our data for melanoma (46% cases with
mutation) and thyroid carcinoma (not yet reported by
OncoKB, 56% cases with mutation) for further analysis.
The actionable mutations create discriminable groups of
cases for thyroid carcinoma (sdis = − 2.07; p = 0.0; srand = −
1.0e−4) and melanoma (sdis =− 0.10; p = 4.7e−3; srand = −
1.1e−4). For thyroid carcinoma, the protein expression of
Fibronectin is altered. For melanoma, the levels of
MAPK_pT202_Y204, PTEN, and Bcl-2 are decreased, and
IGFBP2, E-Cadherin, Akt_pT308, and Akt_pS473 are in-
creased. With no significant proteins intersecting between
the two tumor types, no cross-cancer effect can be identi-
fied for BRAF.
CDK4 amplification is actionable for differentiated sar-
comas (OncoKB level 2). CDK4 status testing reveals
discriminable protein profiles for sarcomas and also for
histotypes renal clear cell carcinoma, lung adenocarcinoma,
breast cancer, ovarian carcinoma, thyroid carcinoma,
low-grade glioma, adrenocortical carcinoma, and lung
squamous cell carcinoma (all not yet reported by OncoKB).
For sarcoma, 36% of the cases show CDK4 amplification
and protein profiles are discriminable (sdis = − 0.34; p = 0.0;
srand = − 6.0e−5) with E-Cadherin, Caveolin-1, Akt_pS473,
Cyclin_B1, ER-alpha, Akt_pT308, YAP_pS127, S6_pS240_
S244, and Cyclin_E1 decreased and HSP70, Syk, Lck,
Src_pY416, and Src_pY527 increased in CDK4 amplified
cases. There is no cross similarity for CDK4.
Fig. 5 Analysis of differential effects of actionable mutations on protein profiles across cancers. Protein profiles are compared for cases with and
without the respective actionable mutations. For certain cases, the presence of an actionable mutation has no visible effect on the level or
proteins (red), for other cases (green) protein profiles are distinguishable for mutated vs. wild-type cases. Among these, pairs of four actionable
genes and 11 cancer types exist, where the actionable mutations have a similar/same directional effect on protein profiles across cancers (blue)
suggesting a similar (patho)mechanistic effect of the actionable mutations in these histological tumor types (compare also Fig. 6)
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EGFR mutations are actionable in non-small cell lung
cancer (OncoKB level 1). Lung adenocarcinoma is the only
histological tumor type with enough cases having an action-
able mutation to perform our analysis. Lung adenocarcin-
oma (LUAD) cases with actionable mutation of EGFR are
discriminable from those without by protein profile
(sdis = − 0.44; p = 5.9e−4; srand = 3.1e−5). EGFR_pY1068
levels are increased for cases with the respective muta-
tions, and Claudin-7 levels are decreased among those
cases.
ERBB2/HER2 amplification is actionable in breast cancer
and gastric cancer (level 1 evidence, FDA-approved). We
find that ERBB2/HER amplification status significantly in-
fluences protein expression profiles not only in breast and
gastric cancer but also in lung squamous cell carcinoma
and lung adenocarcinoma (in conformity with OncoKB
level 4 data) and other 11 not yet reported histological types
(endometrial carcinoma, renal papillary cell carcinoma, tes-
ticular germ cell tumors, urothelial bladder carcinoma,
renal clear cell carcinoma, colon carcinoma, ovarian carcin-
oma, thymoma, thyroid carcinoma, cervical carcinoma,
head and neck squamous cell carcinoma)—see also Fig. 5
or for details Additional file 3. For ten histological tumor
types (melanoma, esophageal carcinoma, glioblastoma,
mesothelioma, cholangiocarcinoma, rectal adenocarcin-
oma, sarcoma, pancreatic adenocarcinoma, uterine carci-
nosarcoma, low-grade glioma), no influence on available
protein expression profiles is found. The discriminability
score sdis for Her2-amplified breast cancers is sdis = − 0.43
(p = 0.0). The mean random discriminability score (mean
discriminability score for one million random class assign-
ments) is srand = − 6.2e−5. We identify characteristic pro-
teins for ERBB2 amplification: HER2_pY1248, HER2,
ACC1, and EGFR_pY1068 (increased levels in amplified
cases) and Bcl-2 and PR (decreased levels—Fig. 6 illus-
trates in details characteristic proteins for ERBB2, FGFR1,
IDH1, and KRAS-NRAS). For gastric cancer, actionable
cases are discriminable from non-amplified cases (sdis
= − 0.18; p = 6.0e−6; srand = − 5.4e−5). The amplified
cases show a decrease of Caspase-7_cleavedD198 and
STAT5-alpha expression levels and an increase of
HER2, ACC1, ACC_pS79, HER2_pY1248, and
Cyclin_E1 expression levels. For ten pairs of histological
tumor types, a similar change in protein expression —a
cross-cancer effect— is found. Two histological tumor
types in which ERBB2 amplification has a similar impact
on proteins are breast (BRCA) and gastric (STAD) cancers
(p = 2.3e−3). HER2_pY1248, HER2, and ACC1 have sig-
nificantly higher mean levels in ERBB2-amplified cases in
both histotypes. Other pairs of similarly influenced histo-
logical tumor types are lung adenocarcinoma and lung
squamous cell carcinoma (p = 5.9e−6; proteins: Caveolin1,
p70S6K, ACC_pS79, ACC1, Rb_pS807_S811) and breast
cancer and ovarian carcinoma (p = 9.0e−6; proteins:
HER2_pY1248, HER2, ACC1, EGFR_pY1068). For lung
adenocarcinoma, cell line drug response data analysis
shows sensitivity for cell lines with actionable mutation.
This fact correlates to the cross-cancer effect of lung
adenocarcinoma to breast cancer and gastric cancer, for
which ERBB2 is actionable.
For FGFR1 amplification, clinical evidence (OncoKB
level 3) exists on its actionability in lung squamous cell
carcinomas. Our analysis shows that besides lung squa-
mous cell carcinoma, protein expression of amplified
cases is discriminable from non-amplified cases in renal
clear cell carcinoma, testicular germ cell tumors, lung
adenocarcinoma, endometrial carcinoma, breast cancer,
and thymoma (all currently not reported by OncoKB).
For lung squamous cell carcinoma, the protein profiles
of the amplified cases have significant differences from
those without amplification (sdis = − 0.08; p = 4.1e−4;
srand = 1.4e−5). Beta-Catenin, 53BP1, and HER2 are de-
creased in amplified cases whereas 4E-BP1 expression
values are increased. A cross-cancer effect is found be-
tween breast cancer and lung adenocarcinoma with
HER2, HER2_pY1248, and EGFR_pY1068 levels decrease
and 4E-BP1 levels increase associated with FGFR1 amplifi-
cation for both histological tumor types.
Certain FGFR3 mutations are actionable in bladder
cancer (OncoKB level 3). Targetable FGFR3 mutations
are only frequent enough in urothelial and bladder car-
cinoma for our analysis. The protein profiles of cases
with at least one of these mutations are discriminable
from the profiles of those without (sdis = − 0.76; p = 2.7e−3;
srand = − 1.3e−5). E-Cadherin, beta-Catenin, HER2, Ku80,
PTEN, IRS1, and 53BP1 are increased among cases having
one or more specific FGF3 mutation.
IDH1 mutations are actionable in acute myeloid
leukemia, cholangiocarcinoma, and glioma (OncoKB level
3). Specific IDH1 mutations lead to discriminable protein
profiles for low-grade glioma (sdis = − 0.47; p = 0.0;
srand = − 3.1e−6) and glioblastoma (sdis =− 1.59; p= 5.0e−4;
srand =− 1.0e−5). For low-grade glioma cases with an action-
able mutation, protein profiles of EGFR_pY1068, HER2_
pY1248, HER2, IGFBP2, EGFR_pY1173, and STAT5-alpha
are decreased. For glioblastoma IGFBP2, EGFR_pY1068,
HER2_pY1248, Caveolin-1, Akt_pT308, Fibronectin, Col-
lagen_VI, and EGFR_pY1173 are decreased in the group of
mutated cases. Therefore, IGFBP2, EGFR_pY1068, HER2_
pY1248, and EGFR_pY1173 are affected in the same way by
IDH1 mutations in low-grade glioma and glioblastoma, and
we report a cross-cancer effect for those groups.
KIT mutations are actionable in gastrointestinal stro-
mal tumors (OncoKB level 1). For the tested KIT muta-
tions, only testicular germ cell tumors (TGCT) had
enough mutated cases sufficient for our analysis. The
protein profiles of the mutated and wild-type cases are
discriminable (sdis = − 0.90; p = 4.5e−3; srand = − 2.6e−4)
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Fig. 6 Identification of proteins characteristic of cross-cancer effects. Four out of the 12 studied actionable genes were found to have cross-
cancer effects on the level of available protein profiles (compare Fig. 5). Proteins were evaluated for their role in discriminating between wild-type
and mutated actionable genes. Bold border outlines indicate statistically significantly characteristic proteins for the given histological tumor type
(rows). Brackets indicate the pairs of histological tumor types for which the actionable mutations show the same directional effects (indicated by
an overlap of characteristic proteins with same directional change). Histotype names with cross-cancer effect are colored blue. For a comprehensive
analysis of characteristic proteins for all actionable genes, see Additional file 1: Figure S5
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with decreased E-Cadherin and Fibronectin expression
in wildtype cases and increased c-Kit, STAT5-alpha, and
Syk expression levels. The results for KIT presented
above are those for mutations typically treated with Ima-
tinib; we also tested mutations treated with other
KIT-inhibitory drugs yielding similar results.
KRAS/NRAS mutations are therapeutically relevant for
melanomas, colorectal cancer, and thyroid cancer (OncoKB
level 3). Specific KRAS/NRAS mutations are correlated
with differences in protein profiles for melanomas and
thyroid cancer and also for testicular germ cell tumors,
endometrial carcinoma, and lung adenocarcinoma (in
conformity with OncoKB level 4 data). No discrimin-
ability of protein profiles can be found for colon carcin-
oma (sdis = − 5.3e−3; p = 0.43; srand = − 6.2e−3) and rectum
adenocarcinoma (sdis = + 0.16; p = 0.59; srand = 0.027).
KRAS/NRAS mutations in colorectal adenomas are the
only occurrence where we cannot find discriminable pro-
tein profiles between cases that would be treated and
those which would not. For melanoma (sdis = − 0.16;
p = 1.0e−3; and = 5.2e−6) E-Cadherin, Caveolin-1, and
c-Kit expression levels are decreased for mutated
cases, and MAPK_pT202_Y204 is increased. For thy-
roid carcinoma (sdis = − 1.53; p = 0.0; srand = − 3.0e−4),
the level of Fibronectin is decreased in mutated
cases. For lung adenocarcinoma and endometrial car-
cinoma, we observed a cross-cancer effect for KRAS/
NRAS-mutated cases as ATM levels are decreased,
and MAPK_pT202_Y204, Claudin-7, S6_pS235_S236,
and MEK1_pS217_S221 are increased in both histo-
logical tumor types consistently.
MDM2 amplification is actionable in liposarcoma
(OncoKB level 3). Besides sarcoma, the protein profiles of
cases with MDM2 amplification are discriminable from
those with normal copy numbers for renal clear cell car-
cinoma, lung adenocarcinoma, thyroid carcinoma, breast
cancer, ovarian carcinoma, and low-grade glioma (all cur-
rently not reported by OncoKB). Protein levels of sarcoma
cases with MDM2 amplifications are discriminable from
those without, with a dissimilarity score of sdis = − 0.41 (p
= 0.0; srand = − 8.9e−5). Amplified cases show decreased
levels of E-Cadherin, Akt_pS473, Akt_pT308, ER-alpha,
Caveolin-1, S6_pS240_S244, S6_pS235_S236, and
Cyclin_B1 and increased levels of HSP70, Syk, and Lck.
No consistent cross-cancer effect is found.
MET amplification is actionable in non-small cell lung
cancers and renal cell carcinoma (OncoKB level 2). In
addition to these histotypes, we found 11 other histo-
logical tumor types (renal clear cell carcinoma, low-grade
glioma, renal papillary cell carcinoma, colon carcinoma,
thyroid carcinoma, thymoma, sarcoma, lung adenocarcin-
oma, testicular germ cell tumors, prostate adenocarcin-
oma, glioblastoma, breast and ovarian carcinoma) where
MET amplification is associated with a significant change
in protein expression. For lung adenocarcinoma, the dis-
criminability score is sdis = − 0.067 (p = 1.5e−3; srand = 2.0e
−5). Proteins that are characteristic of MET amplification
status are cyclin_E1, ASNS, cyclin_B1, ACC1, Fibronectin,
and ACC_pS79 (increased levels), and c-Kit, Caveolin-1,
and Claudin-7 (decreased levels). MET amplification is
present in renal clear cell carcinoma cases, and protein
profiles of amplified and non-amplified cases can be dis-
criminated (sdis = − 0.18; p = 0.0; srand = − 2.0e−5;
Src_pY527, Bcl-2, beta-Catenin, PTEN, MAPK_pT202
_Y204 are decreased in amplified cases and ACC1,
Cyclin_B1, ASNS, ACC_pS79, and Transglutaminase are
increased). We did not observe any similar effect of MET
amplification on protein expression in other histological
tumor types.
PIK3CA activating mutations are actionable for breast
cancer (OncoKB evidence level 3). Besides breast cancer,
we find an impact on protein profiles for gastric cancer
and endometrial carcinoma. OncoKB level 4 data lists all
available histological tumor types as possibly actionable
for PIK3CA activating mutations. Yet no protein level
effect is found for cervical carcinoma, head and neck
squamous cell carcinoma, lung adenocarcinoma, urothe-
lial bladder carcinoma, esophageal carcinoma, low-grade
glioma, lung squamous cell carcinoma, and uterine carci-
nosarcoma. Breast cancer cases with PIK3CA-activating
mutations are discriminable from those without (sdis = −
0.52; p = 0.0; srand = 6.2e−6) with specific proteins (in-
creased levels) PR, ER-alpha, MAPK_pT202_Y204, Fibro-
nectin, AR, and GATA3 in mutated cases and Cyclin_B1,
Cyclin_E1, ASNS, and HER2 being decreased. As there is
no significant overlap of altered proteins between breast
cancer, gastric cancer, and endometrial carcinoma, no
cross-cancer effect was found.
Discussion
Although clinical parameters still outweigh the relevance
of molecular profiles for predicting patient survival [25],
genomic medicine predicting therapies driven by
next-generation sequencing techniques has started to
transform diagnostics and oncological therapy during
the last decade from a discipline that largely relied on
conventional chemotherapies to one that increasingly
exploits knowledge on therapeutically targetable onco-
genic mechanisms. The view on molecular properties
has questioned the relevance of organ- and tissue-typing
in tumors and led to proposals to focus on molecular ra-
ther than histological concepts of cancer classification.
However, many open questions remain because apart
from mutations with unknown functional effects, it is
often not possible even for oncogenic mutations with
established clinical relevance in one cancer type to trans-
fer knowledge of actionability to another cancer type.
Moreover, even for a given cancer, clinical response to
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therapy targeting a specific mutation strongly varies,
which is likely due to the modulatory influence of the
usually high mutational complexity in tumors.
Because proteins carry out most genetically defined
cellular functions, our computational analysis relates
genetic alterations and histology with protein profiles
to estimate their functional effects and offer a way of
evaluating molecular tumor classifications and action-
able genes across cancers. To this end, we measured
how classes from the four studied molecular classifi-
cations are discriminable on the level of protein ex-
pression and phosphorylation based on a panel of 120
cancer-associated proteins available through The Can-
cer Proteome Atlas. The results showed only a partial
histotype-independence, which is indicated by overall
low classification effectivity scores for those classifica-
tion that rely only on mutational profiles (Ciriello
CES = 17.5%, Heim CES = 2%, genetic complexity
reduction-based classification CES = 16.8%). In con-
trast to this, the classification by Hoadley et al. which
combines genomic and proteomic information shows
CES of 80% indicating that proteins have a substantial
influence. Our results also show that even though a
number of molecular classes of these four molecular
classifications are reflected by the protein profiles, the
characteristic proteins of the different classes are not
identical. This indicates that identical genetic alter-
ations are not translated into protein profiles in the
same way in different histotypes. The only exception
was one cross-cancer effect found in the classification
by Heim et al. where the protein profiles between
classes “toSTAD” and “toTHCA” showed same direc-
tional changes in breast cancer and gastric cancer (of
note, more cross-cancer effects were found for the ac-
tionable gene analysis, see below).
These observations are largely consistent with the re-
sults of the actionable gene analysis which showed spe-
cific protein signatures for 12 actionable genes in the
corresponding cancer types from the OncoKB database.
In addition to showing that our analysis identifies
protein-level effects for known actionable genes and cor-
responding cancer types, our approach also identified
protein-level alterations indicative of potential novel ac-
tionable gene—cancer combinations that are so far un-
known according to OncoKB including level 4 evidence
(biological information). This includes ERBB2/HER2
amplification in endometrial carcinoma, renal papillary
carcinoma, testicular germ cell tumors, urothelial carcin-
oma, renal clear cell carcinoma, colon carcinoma, ovar-
ian carcinoma, thymoma, thyroid carcinoma, cervical
carcinoma, and head and neck squamous cell carcinoma.
For MET amplification, our approach predicts effects for
renal clear cell carcinoma, low-grade glioma, renal pa-
pillary carcinoma, colon carcinoma, thyroid carcinoma,
thymoma, sarcoma, lung adenocarcinoma, testicular germ
cell tumors, prostate adenocarcinoma, glioblastoma, breast
cancer, and ovarian carcinoma; for FGFR1 amplification:
renal clear cell carcinoma, testicular germ cell tumors, lung
adenocarcinoma, endometrial carcinoma, breast cancer,
thymoma; MDM2 amplification renal clear cell carcinoma,
lung adenocarcinoma, thyroid carcinoma, breast cancer,
ovarian carcinoma, and low-grade glioma; BRAF V600:
thyroid carcinoma; CDK4 amplification: renal clear cell
carcinoma, lung adenocarcinoma, breast cancer, ovarian
carcinoma, thyroid carcinoma, low-grade glioma, adreno-
cortical carcinoma, and lung squamous cell carcinoma.
Among the predicted genes, the most promising can-
didates for cross-cancer therapies are ERBB2/Her2,
FGFR1, IDH1, and KRAS because our analysis finds
consistent protein profile changes across histotypes
(ERBB2/Her2 among others breast cancer – gastric
cancer, FGFR1: breast cancer – lung adenocarcinoma,
IDH1: low-grade glioma – glioblastoma and KRAS:
lung adenocarcinoma – endometrial carcinoma) for
these genes. The fact that our approach also identifies
the well-known trans-cancer efficacy of ERBB2/Her2
inhibition in breast and gastric cancer [7, 8] supports
the potential clinical value of our predictions.
Interestingly, actionable genes with copy number alter-
ations showed effects on protein expression for more
histotypes than those with simple somatic mutations
(10.2 affected tumor types on average for amplifications
vs. 2.14 for simple somatic mutations).
To validate our findings, we used drug response data
from cell line repositories. The results show that our
computational proteomic analysis using data from The
Cancer Genome Atlas correctly predicts drug response
in an independent data set of cell lines.
A study also linking proteomic and mutation data by
Akbani et al. [26] clusters cases based on proteomic data,
but clustering is evaluated by survival time. Akbani et al.
also report relations between differences in frequencies of
certain mutations between clusters and the differences in
survival statistics for these clusters. In contrast to this
study, our approach relies on mutational data as clustering
or classification input and evaluates classification based
on proteomic data and is therefore also capable of evaluat-
ing the effect of a single mutation directly.
A limitation of our study is that data on only 120 pro-
teins measured for all cases were available. It cannot be
excluded (and is perhaps even likely) that more compre-
hensive protein profiles would lead to the identification of
additional observable protein-level effects of genetic clas-
sifications because in the currently available profiles, cer-
tain aspects of cellular function are simply not covered.
However, the proteins included in the panel had been se-
lected to represent major cancer-related functional and
signaling pathways such as, for example, DNA damage,
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hormone signaling, and proliferation deduced from a
comprehensive mass spectrometry-based dataset [26].
While this may still lead to a slightly too pessimistic view
on the global molecular tumor classifications, it is there-
fore unclear to what extent the inclusion of more proteins
would add to functionally and clinically relevant informa-
tion. With respect to the actionable gene analysis, our ap-
proach may underestimate the number of potentially
druggable genes, but the fact that it readily identifies many
well-established actionable gene, cancer combinations,
such as, for instance, HER2 amplification in breast and
gastric cancer [7, 8], indicates its validity.
The approach we present facilitates analyses of the rela-
tionship between genomic and proteomic profiles in the
context of different histological tumor types. It is import-
ant to note that the ability of our study to reveal
cross-cancer effects is limited by the molecular classifica-
tions we evaluate here. With the advance of our under-
standing of cancer, improved molecular classifications and
more detailed definitions of the actionability of genes will
become available. The method presented in this study is
independent of those changes and therefore can be also
applied to evaluate future definitions. Future molecular
tumor typing concepts are likely to also include additional
aspects such as intratumoral heterogeneity which will be-
come increasingly important for the interpretation of mo-
lecular profiles [27, 28].
Conclusions
While the current tumor classification system is still largely
based on histology, it will be increasingly complemented by
molecular profiling to meet the requirements of precision
medicine. Our analysis shows that tumor typing solely
based on mutational profiling is incomplete. By evaluating
protein-level effects of genetic aberrations, our approach fa-
cilitates the identification of functionally relevant mutations
and may therefore contribute to predicting actionable mu-
tations across cancers and to guide basket trial design.
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